BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ueno M, Takeda H, Takai A, Seno H. Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives. World J Gastroenterol 2022; 28(27): 3410-3421 [PMID: 36158261 DOI: 10.3748/wjg.v28.i27.3410] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Ueno M, Kayahara T, Takabatake H, Morimoto Y, Mizuno M. Clinical characteristics and diagnostic process of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. Acta hepatologica Japonica 2023;64:122-131. [DOI: 10.2957/kanzo.64.122] [Reference Citation Analysis]
2 Kohlhepp MS, Liu H, Tacke F, Guillot A. The contradictory roles of macrophages in non-alcoholic fatty liver disease and primary liver cancer-Challenges and opportunities. Front Mol Biosci 2023;10:1129831. [PMID: 36845555 DOI: 10.3389/fmolb.2023.1129831] [Reference Citation Analysis]
3 Laface C, Ranieri G, Maselli FM, Ambrogio F, Foti C, Ammendola M, Laterza M, Cazzato G, Memeo R, Mastrandrea G, Lioce M, Fedele P. Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma. Cancers (Basel) 2023;15. [PMID: 36765612 DOI: 10.3390/cancers15030654] [Reference Citation Analysis]
4 Zhang K, Yu M, Liu H, Hui Z, Yang N, Bi X, Sun L, Lin R, Lü G. Upregulated TUBG1 expression is correlated with poor prognosis in hepatocellular carcinoma. PeerJ 2022;10:e14415. [PMID: 36523478 DOI: 10.7717/peerj.14415] [Reference Citation Analysis]